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BACKGROUND. Chronic kidney disease (CKD) is strongly associated with cardiovascular disease 
and there is an established association between vasculopathy affecting the kidney and eye. 
Optical coherence tomography (OCT) is a novel, rapid method for high-definition imaging 
of the retina and choroid. Its use in patients at high cardiovascular disease risk remains 
unexplored.
METHODS. We used the new SPECTRALIS OCT machine to examine retinal and retinal nerve 
fiber layer (RNFL) thickness, macular volume, and choroidal thickness in a prospective cross-
sectional study in 150 subjects: 50 patients with hypertension (defined as a documented clinic 
BP greater than or equal to 140/90 mmHg (prior to starting any treatment) with no underlying 
cause identified); 50 with CKD (estimated glomerular filtration rate (eGFR) 8–125 ml/min/1.73 
m2); and 50 matched healthy controls. We excluded those with diabetes. The same, masked 
ophthalmologist carried out each study. Plasma IL-6, TNF-α , asymmetric dimethylarginine 
(ADMA), and endothelin-1 (ET-1), as measures of inflammation and endothelial function, were 
also assessed.
RESULTS. Retinal thickness, macular volume, and choroidal thickness were all reduced in CKD 
compared with hypertensive and healthy subjects (for retinal thickness and macular volume P 
< 0.0001 for CKD vs. healthy and for CKD vs. hypertensive subjects; for choroidal thickness P < 
0.001 for CKD vs. healthy and for CKD vs. hypertensive subjects). RNFL thickness did not differ 
between groups. Interestingly, a thinner choroid was associated with a lower eGFR (r = 0.35, 
P <0.0001) and, in CKD, with proteinuria (r = –0.58, P < 0.001) as well as increased circulating 
C-reactive protein (r = –0.57, P = 0.0002), IL-6 (r = –0.40, P < 0.01), ADMA (r = –0.37, P = 0.02), 
and ET-1 (r = –0.44, P < 0.01). Finally, choroidal thinning was associated with renal histological 
inflammation and arterial stiffness. In a model of hypertension, choroidal thinning was seen 
only in the presence of renal injury.
CONCLUSIONS. Chorioretinal thinning in CKD is associated with lower eGFR and greater 
proteinuria, but not BP. Larger studies, in more targeted groups of patients, are now needed 
to clarify whether these eye changes reflect the natural history of CKD. Similarly, the 
associations with arterial stiffness, inflammation, and endothelial dysfunction warrant further 
examination.
TRIAL REGISTRATION. Registration number at www.clinicalTrials.gov: NCT02132741.
SOURCE OF FUNDING. TR was supported by a bursary from the Erasmus Medical Centre, 
Rotterdam. JJMHvB was supported by a bursary from the Utrecht University. JRC is supported 
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Introduction
Cardiovascular disease (CVD) remains the leading cause of  death worldwide, contributing to ~30% of  all 
deaths globally in 2010 (1). Arterial hypertension is a major risk factor for atherosclerosis, coronary artery 
disease, stroke, and chronic kidney disease (CKD), and is one of  the most prominent contributors to CVD 
death worldwide (2). Currently, it is estimated that a quarter of  the world’s adult population is hypertensive 
and this number is projected to rise to nearly 30% by 2025 (3). CKD is also common, affecting 6%–11% of  
the world’s population (4), and is strongly associated with incident CVD (5). Hypertension is an indepen-
dent risk factor for CKD progression (6), and is a frequent finding in patients with CKD (7).
Renal microvascular changes are considered important in the development of  CKD. Currently, these 
can only be assessed reliably through renal biopsy, which is not without risk. Furthermore, interval renal 
biopsy, to assess changes in the kidney’s microvasculature over time and in response to therapy, is impracti-
cal. The kidney and eye are remarkably similar in their developmental, structural, and pathogenic pathways 
(8). Interestingly, the renal podocyte is very similar in structure (possessing a large surface area with inter-
digitating foot processes) and function to the vascular pericyte (8), so diseases may manifest themselves 
similarly. Transparency of  the ocular media offers a unique opportunity to directly visualize and image 
chorioretinal microvasculature structures within the eye that may be affected in systemic diseases such as 
arterial hypertension (9) and CKD (10).
Optical coherence tomography (OCT) is a novel, noninvasive, and rapid method for cross-sectionally 
imaging the retina and choroid (11). Recent advances in OCT technology have led to the introduction of  
spectral domain OCT (SD-OCT). In combination with an enhanced depth imaging (EDI) feature, SD-EDI-
OCT enables the identification of  specific cell layers within the retina in high resolution, as well as deeper 
structures such as the choroid, in a way only previously possible in histological samples. The utility of  SD-
EDI-OCT has not previously been reported in patients with hypertension or those with hypertension and 
CKD. We hypothesized that OCT imaging would report structural changes within the retina and choroid in 
patients with hypertension and CKD, in keeping with an increased risk of  CVD, compared with matched, 
healthy controls. Based on our observations, we further explored the mechanistic roles of  inflammation 
and endothelial dysfunction in these changes.
Results
Fifty patients with hypertension, 50 patients with varying degrees of  CKD, and 50 healthy controls were 
recruited into the studies. Subject demographics and medications are shown in Table 1. CKD patients’ 
diagnoses are shown in Supplemental Table 1; supplemental material available online with this article; 
doi:10.1172/jci.insight.89173DS1.
Figure 1 shows the chorioretinal structures and measurements of  interest. Retinal thickness did not 
differ between healthy volunteers and subjects with hypertension. However, patients with CKD had a thin-
ner retina at both inner and outer locations of  the Early Treatment Diabetic Retinopathy Study (ETDRS) 
map on the macula; retinal thinning was particularly apparent at the 4 outer locations — outer nasal, 
outer superior, outer temporal, and outer inferior (Figure 2, P < 0.0001 for CKD vs. healthy and for CKD 
vs. hypertensive subjects). The retina was ~10% thinner at these outer positions in CKD compared with 
the other 2 groups, and at all positions women had thinner retinas than men (P < 0.05). In keeping with 
a thinner retina, CKD patients had a reduced macular volume compared with both patients with hyper-
tension and healthy volunteers (P < 0.0001 for both) (Figure 3). However, macular volume did not differ 
between healthy and hypertensive subjects. In both healthy and hypertensive subjects, age correlated with 
retinal thickness (at all locations) and with macular volume, such that older subjects had thinner retinas and 
lower macular volume (data not shown). In CKD, retinal thickness was not associated with age. However, 
macular volume was reduced in older subjects (r = –0.33, P = 0.02). Neither retinal thickness nor macular 
by a Rowling Scholarship. SB was supported by a Wellcome Trust funded clinical research 
fellowship from the Scottish Translational Medicine and Therapeutics Initiative, and by a 
Rowling Scholarship, at the time of this work. ND is supported by a British Heart Foundation 
Intermediate Clinical Research Fellowship (FS/13/30/29994).
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volume related to systolic BP (SBP), diastolic BP (DBP), estimated glomerular filtration rate (eGFR), or 
proteinuria in any of  the 3 subject groups. For macular volume, the area under the receiver operator curve 
(ROC) was 0.82 (95% CI 0.74–0.91; curve not shown). Supplemental Table 2 lists the derived sensitivities 
and specificities at different cutoff  values for macular volume. A value of  less than 8.55 mm3 yielded good 
sensitivity and specificity for the detection of  CKD.
Retinal nerve fiber layer (RNFL) thickness did not differ between the 3 subject groups studied (Fig-
ure 4). Choroidal thickness did not differ between healthy volunteers and patients with hypertension at 
the 3 locations assessed (Figure 5; location I was 2 mm nasal to the fovea; location II was directly over 
the fovea (subfoveal choroidal thickness); location III was 2 mm temporal to the fovea). Interestingly, 
CKD was associated with a thinner choroid at each of  these locations compared with healthy and hyper-
tensive patients (P < 0.001 for both), a reduction in choroidal thickness of  ~15%–20% (Figure 5 and 
Supplemental Videos 1–4). For subfoveal choroidal thickness, the area under the ROC was 0.81 (95% 
CI 0.72–0.89; curve not shown). Supplemental Table 2 lists the derived sensitivities and specificities at 
different cutoff  values for choroidal thickness. A value of  less than 277 μm yielded good sensitivity and 
specificity for the detection of  CKD.
Table 1. Baseline subject characteristics
Parameter Healthy (n = 50) Hypertensive (n = 50) CKD (n = 50)
Demographic
Age, years 50 ± 8 54 ± 15 53 ± 16
Male sex, n (%) 28 (56) 30 (60) 33 (66)
Smoking status
Never 33 32 37
Current 4 6 4
Ex-smoker 13 12 9
Clinical
BMI, kg/m2 25.5 ± 4.3A 28.2 ± 4.5 26.9 ± 5.0
Blood pressure, mmHg
Systolic 129 ± 14 149 ± 19B 134 ± 17
Diastolic 81 ± 9 90 ± 14B 78 ± 10
MAP 95 ± 16 110 ± 13B 96 ± 10
Creatinine, μmol/lC 74 ± 11 79 ± 18 219 ± 126D
CKD stage
1 – – 2
2 – – 8
3 – – 20
4 – – 13
5 – – 8
Estimated GFR, ml/min /1.73 m2 98 ± 13 88 ± 19 37 ± 23D
Hemoglobin, g/l 145 ± 17 141 ± 20 122 ± 17D
hsCRP, mg/l 2 ± 3E 5 ± 7 8 ± 14
Urine P:Cr, mg/mmol – – 194 ± 209
Medications, n (%)
ASA – 2 (4) 10 (20)
α-blocker – 2 (4) 12 (24) 
ACE inhibitor – 19 (39) 27 (53)
ARB - 14 (29) 16 (31)
β-blocker – 7 (14) 13 (25)
Calcium channel blocker – 15 (31) 23 (45)
Diuretic – 8 (16) 10 (20)
Statin – 12 (24) 28 (55)
Values are given as mean ± SD. ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; 
GFR, glomerular filtration rate; MAP, mean arterial pressure; P:Cr, protein/creatinine ratio. AP < 0.05 vs. hypertensive subjects; BP < 0.0001 vs. hypertensive 
and vs. CKD subjects; CTo convert to mg/dl, multiply by 0.0113; DP < 0.0001 vs. healthy and vs. hypertensive subjects; EP < 0.01 vs. CKD; –, not indicated.
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Choroidal thickness in CKD. In patients with hypertension and CKD, increasing age was associated with 
a thinner choroid (r = –0.55, P < 0.001 for locations I, II, and III for hypertension; r = –0.38, P < 0.05 for 
locations I, II and III for CKD) but this was not the case in healthy subjects. However, SBP correlated 
inversely with choroidal thickness in healthy (r = –0.32, P < 0.05 for locations II and III) but not in diseased 
subjects; DBP did not correlate with choroidal thickness in any of  the 3 groups.
In those with CKD, a thinner choroid — at each of  the 3 locations assessed — was also associated 
with a higher serum C-reactive protein (CRP) concentration, a lower eGFR, and greater degrees of  protein-
uria (Figure 6). Interestingly, when all subjects were included in the analysis, this correlation with eGFR 
remained (Supplemental Figure 1). Based on these observations, we measured plasma IL-6 and TNF-α, 
both important mediators of  systemic inflammation (12), in all subjects. As eGFR and proteinuria are 
Figure 1. This figure shows the chorioretinal structures en face (left images) and as a cross section (right images). The Early Treatment Diabetic Reti-
nopathy Study map divides the macula into 9 subfields. A circular grid is centered over the fovea and consists of 3 concentric rings of diameters 1, 3, and 
6 mm, respectively. (A) The inner and outer rings are further divided into quadrants: temporal, nasal, superior, and inferior (left; see also Figure 2). Retinal 
thickness was defined as the area between the internal limiting membrane (ILM) and the hyporeflective line between the retinal pigment epithelium 
(RPE) and the choriocapillaries (right). (B) Retinal nerve fiber layer thickness was defined as the area bordered in red. (C) Choroidal thickness was mea-
sured at 3 locations on the macula: I = 2 mm nasal to the fovea, II = subfoveal, III = 2 mm temporal to the fovea. Scale bars: 200 μm.
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strong, independent vascular risk factors (13), we also went on to 
assess plasma endothelin-1 (ET-1) and asymmetric dimethylargi-
nine (ADMA) as measures of  endothelial function.
Plasma IL-6 was higher in those with hypertension and CKD 
compared with healthy subjects (Table 2, P < 0.05) but did not differ between hypertension and CKD. Whereas 
IL-6 did not associate with choroidal thickness in healthy and hypertensive subjects, a thinner choroid, at all 3 
locations, correlated with a higher concentration of IL-6 in CKD (Figure 7A). Circulating TNF-α was higher in 
CKD compared with both healthy and hypertensive subjects Table 2, P < 0.0001 for both), but unlike IL-6 did 
not associate with choroidal thickness in those with CKD (or in healthy and hypertensive subjects).
Plasma ET-1 was higher in CKD than in healthy and hypertensive patients (Table 2, P < 0.05 for both) 
and also correlated with choroidal thickness in these patients (Figure 7B), such that a higher circulating 
ET-1 was associated with a thinner choroid. Finally, plasma ADMA, which was also higher in those with 
CKD compared with both healthy and hypertensive subjects (Table 2, P < 0.0001 for both), also correlated 
inversely with choroidal thickness (Figure 7C). ET-1 and ADMA showed no associations with choroidal 
thickness in healthy and hypertensive subjects.
Including only those variables with a linear relationship with choroidal thickness into multivariable 
analysis (age, CRP, urine protein/creatinine ratio [P:Cr], IL-6, ET-1, and ADMA) demonstrated that CRP, 
proteinuria, and IL-6 were independent predictors of  choroidal thickness in CKD at locations I and II. Pro-
teinuria was also an independent predictor in location III, as was age (Table 3).
Given the intercorrelation of  the variables included in multivariable analysis we went on to utilize a prin-
cipal component analysis strategy (Supplemental Figure 2). In order to enter normally distributed variables 
into the analysis we first log transformed eGFR, proteinuria, CRP, IL-6, and ET-1. The first 3-component 
axis explained 68.4% of  the total variance, and the first 2-component axis 57.5%. The analysis showed a 
slight opposition in the choroidal location with ADMA, ET-1, IL-6, and proteinuria (first principal com-
ponent). The analysis did not show a different opposition in the 3 choroidal locations and these variables. 
This implies that no one choroidal loca-
tion was more associated than any other 
with any of  the variables assessed. Fur-
thermore, the analysis showed that none 
of  the variables were redundant (except at 
locations II and III, which are very close 
in the first and second axis).
Figure 2. Retinal thickness as a function of macular location. Box-and-
whisker plots showing retinal thickness in subjects with hypertension 
(HT), chronic kidney disease (CKD), and healthy volunteers (HV) across 
different areas of the macula (see Figure 1A): ON, outer nasal; OS, outer 
superior; OT, outer temporal; OI, outer inferior; IN, inner nasal; IS, inner 
superior; IT, inner temporal; II, inner inferior; IC, inner circle. At each of 
the 4 locations ON, OS, OT, and OI, ****P < 0.0001 for CKD vs. healthy and 
for CKD vs. hypertensive subjects. At each of the 5 locations IN, IS, IT, II, 
IC, *P < 0.05 for CKD vs. healthy and for CKD vs. hypertensive subjects. 
The box-and-whisker plots display the first and third quartiles, with the 
line within the box representing the median value. The whiskers denote 
the minimum and maximum values. Thicknesses were examined by 
2-way ANOVA, comparing thicknesses between all 3 patient groups at 
each macular location using Tukey correction for multiple comparisons. 
n = 50 subjects per group.
Figure 3. Macular volume. Box-and-whisker plots showing macular volume 
in subjects with hypertension (HT), chronic kidney disease (CKD), and healthy 
volunteers (HV). ****P < 0.0001 for CKD vs. healthy and for CKD vs. hypertensive 
subjects. The box-and-whisker plots display the first and third quartiles, with 
the line within the box representing the median value. The whiskers denote the 
minimum and maximum values. Volumes were examined by 1-way ANOVA, com-
paring thicknesses between all 3 patient groups at each macular location using 
Tukey correction for multiple comparisons. n = 50 subjects per group.
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Chorioretinal thinning, renal inflammation, and arterial stiffness. Given the associations between chorio-
retinal thicknesses and measures of  systemic inflammation, we explored these relationships with renal his-
tological inflammation. In patients with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis, an 
autoimmune disorder characterized by intense small vessel inflammation in multiple organs often includ-
ing the kidneys, the extent of  glomerular histological inflammation — focal necrotizing lesions and cel-
lular crescents (Supplemental Figure 3, A and B) — did not correlate with retinal thickness. Interestingly, 
we did find a correlation with choroidal thickness, such that a greater degree of  glomerular inflammatory 
injury was associated with a thinner choroid (Supplemental Figure 3, C and D).
Finally, 20 of  our 50 CKD subjects had had previous assessment of  arterial stiffness (14, 15) using 
the gold-standard measure of  pulse wave velocity (PWV) (16). Increased arterial stiffness is a recognized 
marker of  CVD risk (17). The endothelium is an important regulator of  arterial stiffness (18). Increasing 
vascular stiffness as reflected by a higher PWV was associated inversely with choroidal thickness (Supple-
mental Figure 4).
Choroidal thinning in mice with hypertension and renal injury. To explore whether we might be able to 
perform future mechanistic studies to better understand our clinical data, we aimed to use OCT to mea-
sure chorioretinal thicknesses in mice with either hypertension alone or hypertension with associated renal 
injury. Mice with hypertension alone showed no chorioretinal thinning. By comparison, and in keeping 
with our clinical data, animals with matched hypertension and renal injury developed choroidal thinning 
(Supplemental Figure 5), although without evidence of  retinal thinning.
Discussion
We have shown, to our knowledge for the first time, that patients with varying degrees of  predialy-
sis CKD exhibit substantial retinal and choroidal thinning, alongside a reduction in macular volume, 
compared with age- and sex-matched healthy volunteers as well as matched subjects with hyperten-
sion. Interestingly, for the choroid, there were strong correlations between its thickness and the level 
of  systemic inflammation (measured using high-sensitivity CRP 
[hsCRP]) and degree of  renal dysfunction (represented by eGFR 
and proteinuria). Together, these findings suggest that the retinal 
and choroidal changes seen in those with CKD may be represen-
Table 2. Plasma concentrations of IL-6, TNF-α, endothelin-1 (ET-1), and asymmetric dimethylarginine (ADMA) in subjects with 
hypertension, chronic kidney disease (CKD), and healthy volunteers (mean ± SD)
Plasma measure Healthy (n = 50) Hypertensive (n = 50) CKD (n = 50)
IL-6, pg/ml 0.78 ± 0.43A 1.66 ± 2.11 1.87 ± 2.08
TNF-α, pg/ml 1.01 ± 0.73 1.08 ± 0.74 2.16 ± 1.09B
ET-1, pg/ml 1.39 ± 0.80 1.72 ± 0.69 2.29 ± 1.50C
ADMA, nmol/l 295 ± 129 327 ± 160 624 ± 202B
AP < 0.05 for healthy vs. hypertensive and healthy vs. CKD subjects; BP < 0.0001 for CKD vs. healthy and CKD vs. hypertensive subjects; CP < 0.05 for CKD vs. 
healthy and CKD vs. hypertensive subjects.
 
Figure 4. Retinal nerve fiber thickness vs. macular location. Box-
and-whisker plots showing retinal nerve fiber layer (RNFL) thickness 
in subjects with hypertension (HT), chronic kidney disease (CKD), and 
healthy volunteers (HV) across different areas of the macula: T, temporal; 
TS, temporal-superior; NS, nasal-superior; N, nasal; NI, nasal-inferior; TI, 
temporal-inferior. PMB, papillo-macular bundle; N/T, nasal-temporal ratio; 
G, average RNFL thickness. The box-and-whisker plots display the first and 
third quartiles, with the line within the box representing the median value. 
The whiskers denote the minimum and maximum values. Thicknesses 
were examined by 2-way ANOVA, comparing thicknesses between all 3 
patient groups at each macular location using Tukey correction for multiple 
comparisons. n = 50 subjects per group.
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tative of  a generalized systemic microvascular injury, and may also reflect underlying renal injury.
The Chronic Renal Insufficiency Cohort (CRIC) study, which assessed the relationship between CKD 
and retinal pathology, revealed a high prevalence of  fundus pathology in CKD patients, probably because 
half  of  the patients had long-standing diabetes (10). Few studies have made OCT assessments in those with 
CKD and all have included only those with end-stage renal failure (ESRF — mostly due to diabetes) requir-
ing renal replacement therapy (19–21). Thus, ours is possibly the first study to investigate OCT measures 
in those with predialysis CKD. The strong correlations for the associations seen, despite the group of  CKD 
patients not comprising a single disease etiology, suggests that these may be a general feature of  predialysis 
CKD and relatively independent of  underlying diagnosis. While previous studies examining the impact of  
dialysis on retinal and choroidal parameters have shown differences (20, 21), these may largely be attribut-
able to the fluid shifts characteristic of  dialysis. In another study, RNFL thickness was found to be reduced 
in dialysis patients (with ESRF due to reasons other than diabetes) compared with controls (19). In our own 
study we found no difference in RNFL thickness in CKD compared with both healthy and hypertensive 
subjects, but it may be that optic neuropathy is a feature of  late CKD. In keeping with other work, our data 
confirm a negative correlation between choroidal thickness and age (22).
Importantly, and in comparison with CKD, we found no differences between healthy and hypertensive 
subjects in any of  the parameters studied. As for CKD, there are few studies that have examined OCT mea-
sures in patients with hypertension and only 1 with robust methodology (23). Here, Muraoka et al. showed 
that retinal arteriolar and venular wall thicknesses were increased in hypertensive compared with healthy 
subjects. The authors did not study the parameters assessed in the current study. Our own lack of  differ-
ences may be due to a reasonably young cohort (mean age ~50 years) of  solely patients of  European descent 
who had no overt evidence of  end-organ damage — although we only assessed kidney damage by means 
of  serum creatinine (and eGFR) 
and urinalysis and there was no 
assessment of  cardiac or cere-
bral function. These should be 
considered in future studies.
Table 3. Multivariable analysis of factors predicting choroidal thickness in CKD subjects at 3 locations on the macula
Parameter Choroidal LocationA
I II III
Age –0.06 –0.12 –0.32B
hsCRP –0.46B –0.28B –0.22
Urine P:Cr –0.29B –0.43B –0.50B
IL-6 –0.45B –0.29B –0.22
ET-1 –0.11 –0.05 –0.13
ADMA –0.19 –0.15 –0.21
r2 0.68 0.49 0.38
AI = 2 mm nasal to the fovea, II = subfoveal, III = 2 mm temporal to the fovea. BP < 0.05. The table gives standardized regression coefficients (β values). 
ADMA, asymmetric dimethylarginine; hsCRP, high-sensitivity C-reactive protein; ET-1, endothelin-1; P:Cr, protein/creatinine ratio.
Figure 5. Choroidal thickness vs. macular location. Box-and-whisker 
plots showing choroidal thickness in subjects with hypertension (HT), 
chronic kidney disease (CKD), and healthy volunteers (HV) across 3 
locations on the macula: I = 2 mm nasal to the fovea, II = subfoveal, 
III = 2 mm temporal to the fovea. At each of these 3 locations, ***P 
< 0.001 for CKD vs. healthy and for CKD vs. hypertensive subjects. 
The box-and-whisker plots display the first and third quartiles, with 
the line within the box representing the median value. The whiskers 
denote the minimum and maximum values. Thicknesses were exam-
ined by 2-way ANOVA, comparing thicknesses between all 3 patient 
groups at each macular location using Tukey correction for multiple 
comparisons. n = 50 subjects per group.
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The retina is a complex neurovascular tissue. Photoreceptors 
resting on the retinal pigment epithelium form the outer layer, 
and the RNFL the innermost layer. Between the photoreceptors 
and RNFL are the neural processing cells including horizontal, 
amacrine, and bipolar cells synapsing with retinal ganglion cells 
whose axons form the RNFL. It is possible that the reduction in 
retinal thickness and macular volume seen in those with CKD 
is due to the atrophy of  these cells probably as a result of  com-
promised blood supply due to microvascular injury. The choroid 
is a largely vascular organ and so the thinning here is likely to 
reflect purely microvascular damage and loss. As seen in Figure 
2, the reduction in retinal thickness in CKD patients was largely 
restricted to the outer retinal layers. Of  note, the outer third of  the 
retina receives its blood supply from the choroid (with the inner 
two-thirds being retinal in origin). Thus, it is possible the retinal 
changes occur secondary to choroidal pathology, compromising 
choroidal blood flow to the retina. This might also explain, in 
part, the lack of  association between the extent of  retinal thin-
ning and measures such as CRP, eGFR, or proteinuria.
There are a number of  potential explanations for the chang-
es we have observed. Hypertension is an important and com-
mon contributor to microvascular injury in a number of  organs 
including the kidney and the eye (2, 24). However, the retinal 
and choroidal thinning seen in CKD is unlikely to be related to 
BP because differences were not seen between the hypertensive 
cohort and healthy volunteers, even though all components of  
BP were significantly higher in the hypertensive group compared 
with those in our group with CKD. Furthermore, neither retinal 
nor choroidal thickness correlated with SBP or DBP in those 
with CKD. Dysfunction of  the autonomic nervous system may 
contribute to the changes observed. CKD is a state of  heightened 
sympathetic activity and this may contribute to disease progres-
sion (25). While the choroidal circulation has autonomic innerva-
tion, the retinal circulation does not. Thus, the thinning of  the 
outer retina and choroid would be consistent with increased sym-
pathetic tone affecting the choroidal vasculature. We did not investigate measures of  sympathetic activity in 
the current study, but these would be an interesting area for future research.
However, we did see associations between systemic (and renal) inflammation and 2 important vascular 
risk factors, eGFR and proteinuria, and these may go some way in providing a mechanism to explain our 
observations. Inflammation is an important contributor to the development of  cardiovascular and renal dis-
ease. hsCRP correlated inversely with choroidal thickness in CKD and was an independent predictor of  thick-
Figure 6. Correlations of choroidal thickness with clinical measures. 
Correlation of choroidal thickness (at locations I, II, and III on the 
macula), with (A) C-reactive protein (CRP) (Pearson’s correlation), 
(B) estimated glomerular filtration rate (eGFR), and (C) proteinuria 
(Spearman’s correlation) in patients with chronic kidney disease. eGFR 
was calculated using the Modification of Diet in Renal Disease (MDRD) 
equation. Proteinuria was quantified on the basis of a urine total pro-
tein/creatinine ratio (P:Cr). A P:Cr of greater than 15 mg/mmol is abnor-
mal and greater than 300 is considered within the nephrotic range. The 
box-and-whisker plots in B display the first and third quartiles, with 
the line within the box representing the median value. The whiskers 
denote the minimum and maximum values. n = 50 subjects per group. 
Statistically significant differences were assessed with a 2-way ANOVA 
with a Turkey correction for multiple comparisons
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ness. On this basis, we assessed circulating IL-6 and TNF-α, 
both important mediators of  inflammation in CVD and CKD. 
These were raised in CKD patients and IL-6 correlated inverse-
ly with choroidal thickness, consistent with its involvement 
in the process. Indeed, IL-6 is considered to be important in 
the pathogenesis of  a number of  eye conditions (26, 27) and 
is predictive of  outcome in both CVD (28) and CKD (29). 
Therapeutic strategies blocking its effects are currently being 
explored in both eye (30) and cardiovascular (31) disorders, the 
pathology of  which, based on the current data, may be linked.
Given the relationships seen between choroidal thickness 
and both eGFR and proteinuria we assessed endothelial func-
tion. Plasma ADMA, an endogenous inhibitor of  nitric oxide 
synthase, and plasma ET-1 were measured as components of  
the nitric oxide and ET systems, respectively. Both contribute to 
vascular dysfunction in CKD and an imbalance (more ET-1/
less nitric oxide) may contribute to vasoconstriction, inflam-
mation, and atherosclerosis (32, 33). Circulating ADMA was 
~2-fold higher in CKD than in both healthy and hypertensive 
subjects and, in keeping with previous studies, plasma ET-1 
was also increased (34). Both ET-1 and ADMA associated 
strongly, and inversely, with choroidal thickness in those with 
CKD. ET-1 contributes to the vasoconstriction that is seen in 
many eye diseases (35, 36) and blocking its effects improves 
retinal vascular integrity (37). Thus, ET receptor antagonism, 
a novel therapeutic strategy currently being investigated for 
renoprotection in CKD (38), may also have benefits for the eye. 
Furthermore, given that there is often reciprocal upregulation 
of  the nitric oxide system when the ET system is downregulat-
ed (32), an ET-blocking strategy may offset some of  the poten-
tially deleterious effects of  elevated circulating ADMA.
As limitations, medications taken by our patients, such 
as angiotensin-converting enzyme inhibitors, β-blockers, and 
statins may have had effects on the OCT parameters studied. 
However, all patients were stabilized on their therapies and 
this is an unavoidable limitation of  such studies. Further-
more, we observed undulation of  the choroidal-scleral inter-
face, limiting the power of  single-point choroidal thickness 
measurements, and suggesting future studies should examine 
choroidal volume. This quantifies the overall disease burden 
and may be helpful in understanding disease pathophysiology 
and for assessing the response to treatment in chorioretinal 
disorders (39). Finally, our study describes associations and 
so these findings should be explored further following phar-
macological interventions and renal transplantation. Our 
preclinical data are potentially the first to show that choroi-
dal thickness can be assessed in mice and this lends itself  to 
future mechanistic studies.
Figure 7. Correlations of choroidal thickness with nontraditional 
cardiovascular risk factors. Correlation of choroidal thickness (at 
locations I, II, and III on the macula), with (A) IL-6, (B) endothelin-1 
(ET-1), and (C) asymmetric dimethylarginine (ADMA) in patients with 
chronic kidney disease. Correlation coefficients are Spearman’s coef-
ficients. n = 50 subjects per group.
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Conclusions. A growing number of  studies support the link between diseases affecting the eye and the 
kidney. As is the case for CKD, common eye diseases such as age-related macular degeneration (AMD) 
and glaucoma are strongly associated with age and vascular risk factors such as hypertension, diabetes, and 
smoking (8). Furthermore, pathology within the eye, such as retinal microvascular changes, is predictive of  
incident CKD, and patients with CKD may be at higher risk for eye diseases such as AMD and glaucoma 
(8). It would be of  major clinical value if  retinal OCT-derived metrics could be used to detect and moni-
tor vascular injury within the eye at any early stage and as a surrogate measure of  renal vascular injury. 
A recent study has suggested that retinal photography may be useful alongside proteinuria quantification 
in risk-stratifying CKD patients in terms of  disease progression (40). The current data highlight the need 
for larger studies in a similarly diverse CKD population using standardized OCT measurements as well as 
preclinical studies to explore the mechanisms responsible for the changes seen. Such studies would need 
to assess whether OCT measures could provide information on CKD progression beyond that already 
provided by proteinuria and eGFR. They should also establish whether OCT imaging — a quick, simple, 
and noninvasive procedure — might be of  value clinically in assisting diagnosis of  systemic microvascular 
disease, assessing response to therapy, and in the earlier identification of  patients at increased risk of  CVD.
Methods
See Supplemental Information for more information.
Subjects. This was a prospective, cross-sectional controlled study performed at the Anne Rowling Regen-
erative Neurology Clinic at the Royal Infirmary of  Edinburgh. Subjects were recruited from the hyper-
tension and renal outpatient clinics at the Royal Infirmary of  Edinburgh and Western General Hospital, 
Edinburgh. Age- and sex-matched controls without any comorbidity were recruited from the community. 
We used a frequency matching protocol for the recruitment of  patients with hypertension and healthy vol-
unteers. For every 5 patients with CKD recruited we matched these, based on age and sex, with 5 hyperten-
sive patients and 5 healthy volunteers. Hypertension was defined as a documented clinic BP greater than or 
equal to 140/90 mmHg (prior to starting any treatment) with no underlying cause identified. Both incident 
and prevalent patients with hypertension were included. Renal patients were categorized into the 5 stages 
of  CKD on the basis of  the Kidney Disease Outcome Quality Initiative (K/DOQI) classification (7). We 
excluded those with any eye disease, previous eye surgery, refractive error greater than ± 6 diopters, those 
with diabetes mellitus (excluded both on the basis of  the medical history and by checking a fasting glucose 
that had to be < 6 mmol/l), and clinically overt CVD.
Study protocol. All subjects abstained from alcohol-, nicotine-, and caffeine-containing products for 24 
hours, and food for 4 hours, prior to the study but continued their normal medications (except diuretics, 
which were omitted on the study day). All studies were performed at the same time of  day in a quiet, tem-
perature-controlled room using the same OCT equipment by the same ophthalmologist who was masked to 
study group. SBP and DBP were recorded in duplicate, with an appropriately sized cuff, using a validated 
oscillometric sphygmomanometer, the Omron HEM-705CP (41), and values are presented as the average 
of  2 recordings. Creatinine clearance, as an estimate of  GFR, was calculated according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (42).
All subjects underwent a single examination of  both eyes using the Heidelberg SPECTRALIS Spectral-
Domain OCT machine (software version 6.0, Heidelberg Engineering). Each examination comprised 3 scan 
protocols for each eye: (a) a horizontal line scan through the macula, centered over the fovea, with EDI 
enabled for greater choroidal visualization; (b) a macular volume scan consisting of  61 horizontal B-scans 
with a separation of  120 μm covering the whole macular area; and (c) a peripapillary circular line scan cen-
tered over the optic disc, with Nsite Axonal Analytics software automated segmentation of  the RNFL (43).
Measurements recorded included retinal thickness, RNFL thickness, macular volume, and choroidal thick-
ness. The images took advantage of the proprietary TruTrack active eye tracking and Automatic Real-Time 
(ART) software, which averages the image over 100 scans, to generate a single high-resolution scan image. 
OCT measurements of retinal thickness were performed according to the ETDRS protocol (44). The ETDRS 
map divides the macula into 9 subfields. The circular grid is centered over the fovea and consists of 3 concentric 
rings of diameters 1, 3, and 6 mm, respectively. The inner and outer rings are further divided into quadrants: 
temporal, nasal, superior, and inferior (Figure 1). The retinal thickness, RNFL thickness, and macular volume 
were measured using the automatic segmentation values of the SPECTRALIS OCT. The choroidal thickness 
was measured manually, on the horizontal EDI line scan, in 3 separate locations: subfoveal, and 2 mm nasal 
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and 2 mm temporal to the fovea. The measurement was taken in a vertical line from the outer hyper-reflective 
line corresponding to the base of the retinal pigment epithelium (RPE) (RPE/basement membrane complex), 
to the choroidal-scleral junction (Figure 1).
Sample collection and analysis. Venous blood samples for ADMA, ET-1, IL-6, and TNF-α were collected 
in EDTA tubes. These were immediately centrifuged at 2,500 g for 20 minutes at 4°C. Samples were stored 
at –80°C until analysis.
Plasma ADMA concentrations were measured using an optimized and fully validated high-perfor-
mance liquid chromatography method, as previously described (45) (intra- and interassay variations 1.9% 
and 2.3%, respectively). Plasma ET-1, TNF-α, and IL-6 were determined by ELISA (R&D Systems). The 
mean recovery of  ET-1 was greater than 95%. The intra- and interassay variations were 4% and 6%, respec-
tively. The cross-reactivity of  the assay was 23% for ET-2, 0.5% for ET-3, and there was no cross-reactivity 
with big ET-1. For TNF-α, the mean recovery from plasma was 99%. The intra- and interassay variations 
were 6% and 8%, respectively. The cross-reactivity of  the assay was less than 0.5% with related molecules. 
For IL-6 the mean recovery was 97% with intra- and interassay variations of  7%. The cross-reactivity of  
the assay was less than 0.5% with related molecules. Serum hsCRP concentrations were quantified in the 
hospital biochemistry laboratory using a validated latex particle–enhanced immunoturbidimetry technique 
(Vitros 5, 1 FS Chemistry Systems, Ortho-Clinical Diagnostics, Inc.) (intra- and interassay variations 2.3% 
and 5.0%, respectively).
Assessment of  renal histological injury. Of  the 50 subjects with CKD included in the study, 14 had a 
diagnosis of  systemic vasculitis and had had a renal biopsy in the preceding 12 months; all of  these were 
considered adequate for histological assessment (46).
Measurement of  arterial stiffness. PWV was measured by the foot-to-foot wave velocity method using 
the SphygmoCor system (SphygmoCor Mx, AtCor Medical, version 6.31), in which a high-fidelity micro-
manometer (SPC-301, Millar Instruments) was used to determine carotid-femoral PWV (16).
Data storage and statistical analysis. This study was powered on the basis of  a healthy subfoveal choroidal 
thickness of  235 ± 53 μm (47) and a healthy temporal RNFL thickness of  79 ± 16 μm (19). To detect a 15% 
difference in choroidal thickness from normal in those with hypertension or CKD with 90% power and at 
significance level P = 0.05, we needed to include ~22 subjects; for RNFL thickness the corresponding figure 
was ~30 subjects. Thus, we aimed for 35 subjects in each group. Data were stored and analyzed in Prism, 
version 6.0 (GraphPad Software Inc.). Data are presented as mean ± standard deviation (SD). Thicknesses 
were examined by 2-way ANOVA, comparing thicknesses between all 3 patient groups at each macular 
location using Tukey correction for multiple comparisons. For blood measurements, differences between 
groups were assessed using parametric or nonparametric analyses as appropriate and similarly, correlation 
coefficients calculated using the Pearson or Spearman method as appropriate. Stepwise linear regression 
was used for multivariable analysis using variables showing linear relationship with choroidal thickness 
(age, CRP, urine P:Cr, IL-6, ET-1, and ADMA). Significance was set at a P value of  less than 0.05. To mea-
sure the sensitivity and specificity of  macular volume and subfoveal choroidal thickness at different values, 
a conventional ROC curve was generated using healthy subjects as controls. The area under the curve was 
calculated to ascertain the quality of  these OCT metrics as biomarkers of  CKD. An area of  0.5 is no better 
than expected by chance, whereas a value of  1.0 signifies a perfect biomarker.
Study approval. The clinical study was carried out with the approval of  the local research ethics com-
mittee and the written informed consent of  each subject. The investigations conformed to the principles 
outlined in the Declaration of  Helsinki.
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